Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Type 2 Diabetes Treatment

What is Insulin Resistance?

Fibromyalgia and Diabetes

Diabetes Mellitus Type 2 Pathophysiology

What is Diabetes?

Type 2 Diabetes Symptoms

Insulin Resistance Treatment

Insulin Resistance Symptoms

Type 2 Diabetes Screening and Prevention

Insulin Resistance Diagnosis

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

See more featured articles »

Vitamin D and Type 2 Diabetes

Insulin Medication

Causes of Insulin Resistance

The Risks of Prediabetes

Type 2 Diabetes Diagnosis

Living With Type 2 Diabetes

Insulin Resistance Pathophysiology

Diabetes in Men versus Women

Is a Plant-Based Diet Good for Type 2 Diabetes?

Does the Keto Diet Increase the Risk of Diabetes?

Insulin Resistance and Parkinson's Disease

Latest Type 2 Diabetes News and Research

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

AI chatbots wrongly reassure sleep apnea patients, study finds

In a third of cases, AI chatbots wrongly reassure sleep apnea patients that their symptoms are not serious, discouraging them from seeking a referral to a specialist, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

6 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Gestational diabetes history linked to earlier development of type 2 diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in women that develop type 2 diabetes (T2D), those who had gestational diabetes (GD) when pregnant are developing T2D on average almost 13 years earlier than those who did not.

3 Sep 2026

As life expectancy rises, healthy aging is more important than ever

Global disease burden is shifting toward aging-related conditions as people live longer, with these diseases now representing the largest expected lifetime health burden for newborns across all income groups. Modeling suggests that reducing aging-related disease could produce unusually large and progressively greater gains in both longevity and healthy life expectancy because improvements in survival and health reinforce one another.

3 Sep 2026

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Same foods, different timing, very different glucose patterns

In a randomized crossover study of 22 healthy, normal-weight Chinese men, consuming canola oil alone or with spinach before a high-glycemic mashed-potato meal produced flatter post-meal glucose and insulin responses than spinach alone or no preload. The effects were associated with increased GLP-1 signaling and slower gastric emptying, with the findings indicating that the unsaturated oil was the primary driver of the metabolic response.

3 Sep 2026

Study links popular weight-loss drugs to increased male hair loss

Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

3 Sep 2026

AI learned from cardiologists’ notes, and needed far less labeled ECG data

By teaching an AI system to connect raw heart signals with the clinical insights contained in cardiologists’ reports, researchers tested whether routine ECGs could reveal more with far fewer labeled examples.

2 Sep 2026

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026

Your weekend meal schedule may matter more than you think

In a prospective analysis of 104,806 adults from the NutriNet-Santé cohort, greater differences in meal timing between weekdays and weekends were associated with higher risks of cardiovascular disease and coronary heart disease in men over a median 8.1 years. The associations were strongest when weekend eating shifted earlier, while delayed weekend eating was linked specifically to coronary heart disease, with no association detected for cerebrovascular disease.

2 Sep 2026

Digital health coaching moves into routine care for gestational diabetes

Researchers at University College Dublin (UCD) published the full study protocol for Bump2Baby & Me+ (B2B&Me+) today.

2 Sep 2026

Certain diabetes patients face higher ketoacidosis risk with SGLT2 drugs

Patients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing this serious condition when treated with so-called SGLT2 inhibitors.

1 Sep 2026

Flavorings, colors and sweeteners emerge as UPF markers linked to depression risk

A prospective UK Biobank study of 171,818 adults found that greater estimated exposure to foods containing flavorings, coloring agents, and sweeteners was dose-dependently associated with a higher risk of incident depression over 10.7 years. The findings suggest that specific markers, rather than ultra-processed foods uniformly, may help explain associations between UPF consumption and depression risk.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Starting statins early after diabetes diagnosis linked to lower dementia risk

Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026